The concomitant usage of OXYCONTIN and CYP3A4 inducers can decrease the plasma concentration of oxycodone [see Scientific PHARMACOLOGY], leading to reduced efficacy or onset of a withdrawal syndrome in individuals which have designed physical dependence to oxycodone [see WARNINGS AND Safeguards].If employing asymmetric dosing, instruct people to ge